Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Relationship of Peripheral Inflammatory and Neuroprotective Biomarkers With Response to Intermittent Theta Burst Stimulation in Treatment-Resistant Depression (TRD-BIOTMS)

11 september 2026 uppdaterad av: Beyazit Garip, Gulhane Training and Research Hospital

Relationship Between Response to Transcranial Magnetic Stimulation and Peripheral Inflammatory and Neuroprotective Biomarkers in Patients With Treatment-Resistant Depression

Treatment-resistant depression (TRD) is a major clinical challenge affecting a substantial proportion of patients with major depressive disorder who do not adequately respond to conventional antidepressant treatments. Intermittent theta burst stimulation (iTBS), a non-invasive neuromodulation technique targeting the left dorsolateral prefrontal cortex, has emerged as an effective treatment option for these patients. However, the biological mechanisms underlying treatment response remain poorly understood.

This single-center, prospective, investigator-initiated clinical study aims to investigate the effects of iTBS on clinical symptoms, executive functions, and peripheral inflammatory and neuroprotective biomarkers in patients with treatment-resistant depression.

Fifty patients with treatment-resistant depression and fifty healthy control participants will be enrolled. Patients will receive active iTBS treatment for four weeks (20 sessions), while healthy controls will undergo baseline clinical, cognitive, and biological assessments without receiving any intervention.

Clinical outcomes will be evaluated using the 17-item Hamilton Depression Rating Scale (HAM-D-17), Patient Health Questionnaire-9 (PHQ-9), Clinical Global Impression (CGI), and Insomnia Severity Index (ISI). Executive functions will be assessed using the Wisconsin Card Sorting Test, Trail Making Test A and B, and verbal fluency tests.

Peripheral blood samples will be collected before and after treatment to measure inflammatory, neuroplasticity, and neuroprotective biomarkers, including IL-1β, IL-6, IL-10, TNF-α, high-sensitivity C-reactive protein (hs-CRP), brain-derived neurotrophic factor (BDNF), apolipoprotein D (APOD), serum amyloid A1 (SAA1), and serum amyloid A2 (SAA2). Gene expression analyses will also be performed using quantitative polymerase chain reaction (qPCR).

The study aims to identify biological mechanisms associated with iTBS treatment response and to explore potential biomarkers that may predict clinical improvement in patients with treatment-resistant depression. The findings may contribute to the development of personalized neuromodulation strategies and biomarker-guided treatment approaches for depression.

Studieöversikt

Detaljerad beskrivning

Major depressive disorder (MDD) is a highly prevalent psychiatric disorder associated with substantial functional impairment, reduced quality of life, increased suicide risk, and significant socioeconomic burden. Despite the availability of pharmacological, psychotherapeutic, and neuromodulation-based treatments, a considerable proportion of patients fail to achieve adequate clinical improvement and develop treatment-resistant depression (TRD).

Treatment-resistant depression is commonly defined as inadequate response to at least two antidepressant medications administered at adequate doses and durations. Patients with TRD frequently experience chronic symptoms, recurrent episodes, impaired psychosocial functioning, increased healthcare utilization, and poorer long-term outcomes.

Intermittent theta burst stimulation (iTBS) has emerged as an effective, non-invasive neuromodulation treatment for TRD. Compared with conventional high-frequency repetitive transcranial magnetic stimulation (rTMS), iTBS offers substantially shorter treatment sessions while maintaining comparable efficacy. However, the biological mechanisms underlying treatment response remain incompletely understood, and reliable biomarkers predicting therapeutic outcomes have not yet been established.

Accumulating evidence suggests that neuroinflammation, impaired neuroplasticity, oxidative stress, and altered immune regulation contribute to the pathophysiology of depression and may influence treatment response. Therefore, investigating biological changes associated with iTBS may improve the understanding of therapeutic mechanisms and facilitate the development of personalized treatment strategies.

This single-center, prospective, investigator-initiated clinical study aims to comprehensively evaluate clinical outcomes, executive functions, and peripheral inflammatory and neuroprotective biomarkers in patients with TRD receiving iTBS treatment.

A total of 100 participants will be enrolled, including 50 patients with treatment-resistant depression and 50 healthy controls. Patients will receive active iTBS over the left dorsolateral prefrontal cortex using a MagVenture X100 device for 20 sessions administered over four weeks. Healthy controls will not receive any intervention and will participate only in baseline assessments.

Clinical outcomes will be evaluated using the 17-item Hamilton Depression Rating Scale (HAM-D-17), Patient Health Questionnaire-9 (PHQ-9), Clinical Global Impression (CGI), and Insomnia Severity Index (ISI). Executive functions will be assessed using the Wisconsin Card Sorting Test (WCST), Trail Making Test A and B (TMT-A and TMT-B), and verbal fluency tests.

Peripheral blood samples will be collected before and after treatment. Serum levels of IL-1β, IL-6, IL-10, TNF-α, high-sensitivity C-reactive protein (hs-CRP), brain-derived neurotrophic factor (BDNF), apolipoprotein D (APOD), serum amyloid A1 (SAA1), and serum amyloid A2 (SAA2) will be measured using enzyme-linked immunosorbent assays (ELISA). Gene expression analyses of relevant biomarkers will be performed using quantitative polymerase chain reaction (qPCR).

The primary outcome will be the change in HAM-D-17 scores from baseline to week 4. Secondary outcomes will include changes in clinical scales, executive function performance, biomarker levels, and gene expression profiles. Associations between biological markers, cognitive performance, and treatment response will also be examined.

The study seeks to identify potential biomarker signatures associated with iTBS response and contribute to the development of biomarker-guided, personalized neuromodulation strategies for treatment-resistant depression.

Studietyp

Interventionell

Inskrivning (Beräknad)

100

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

      • Ankara, Turkiet (Türkiye), 06000
        • Rekrytering
        • Gulhane Training and Research Hospital
        • Kontakt:
    • Ankara
      • Ankara, Ankara, Turkiet (Türkiye), 06000
        • Har inte rekryterat ännu
        • Gulhane Training and Research Hospital
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen

Tar emot friska volontärer

Ja

Beskrivning

Inclusion Criteria

Treatment-Resistant Depression Group:

Age between 18 and 55 years. Male or female participants. Diagnosis of Major Depressive Disorder according to DSM-5-TR criteria. Inadequate response to at least two antidepressant treatments administered at adequate doses and durations.

Eligible for transcranial magnetic stimulation (TMS) treatment. Able and willing to provide written informed consent. Able to complete neuropsychological assessments. Able to attend study visits and complete the treatment protocol.

Healthy Control Group:

Age between 18 and 55 years. Male or female participants. No current DSM-5-TR psychiatric disorder. Able and willing to provide written informed consent. Able to complete neuropsychological assessments.

Exclusion Criteria

Schizophrenia, bipolar disorder, organic mental disorders, or other major psychiatric disorders.

History of epilepsy, brain tumor, severe head trauma, or significant neurological disease.

Any contraindication to TMS. Presence of intracranial metal implants, cardiac pacemakers, cochlear implants, or other incompatible implanted devices.

Active infection. Autoimmune disease or chronic inflammatory disease. Electroconvulsive therapy, deep brain stimulation, or vagus nerve stimulation within the previous 5 years.

Previous intravenous or intranasal ketamine treatment. Pregnancy or breastfeeding. Active alcohol or substance use disorder. Inability to comply with study procedures. Inability to tolerate the iTBS protocol. Withdrawal of informed consent at any stage of the study.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Active iTBS Treatment
Participants with treatment-resistant depression will receive active intermittent theta burst stimulation (iTBS) over the left dorsolateral prefrontal cortex using a MagVenture X100 device. Treatment will be administered at 90% of the resting motor threshold, with 1800 pulses per session, 5 sessions per week, for a total of 20 sessions over 4 weeks. Participants will continue their routine pharmacological treatments throughout the study. Clinical assessments, neuropsychological testing, and peripheral biomarker analyses will be performed before and after treatment.
Intermittent theta burst stimulation (iTBS) will be administered over the left dorsolateral prefrontal cortex using a CE-marked MagVenture X100 transcranial magnetic stimulation device. Stimulation intensity will be set at 90% of each participant's resting motor threshold. The protocol will consist of bursts of three pulses delivered at 50 Hz, repeated at a frequency of 5 Hz, with 2-second stimulation trains followed by 8-second intertrain intervals. Participants will receive 1800 pulses per session, five sessions per week, for a total of 20 sessions over four weeks (36,000 pulses in total). Participants will continue their routine pharmacological treatments throughout the study, and no investigational medicinal products will be initiated as part of the research protocol.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in Hamilton Depression Rating Scale (HAM-D-17) Total Score
Tidsram: Baseline and Week 4
The primary outcome is the change in the 17-item Hamilton Depression Rating Scale (HAM-D-17) total score between baseline and week 4 following intermittent theta burst stimulation (iTBS) treatment. Clinical response will be defined as a reduction of 50% or greater from baseline, and remission will be defined as a HAM-D-17 total score of 7 or lower.
Baseline and Week 4

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in Patient Health Questionnaire-9 (PHQ-9) Score
Tidsram: Baseline and Week 4
Change in depressive symptom severity measured by the Patient Health Questionnaire-9 (PHQ-9) following iTBS treatment.
Baseline and Week 4
Change in Insomnia Severity Index (ISI) Score
Tidsram: Baseline and Week 4
Change in insomnia severity following iTBS treatment.
Baseline and Week 4
Change in Wisconsin Card Sorting Test Performance
Tidsram: Baseline and Week 4
Change in executive function performance assessed using the Wisconsin Card Sorting Test
Baseline and Week 4
Change in Peripheral Inflammatory Biomarker Levels
Tidsram: Baseline and Week 4
Change in IL-1β, IL-6, IL-10, TNF-α, and high-sensitivity C-reactive protein (hs-CRP) levels following iTBS treatment.
Baseline and Week 4
Change in Neuroprotective Biomarker Levels
Tidsram: Baseline and Week 4
Change in BDNF, APOD, SAA1, and SAA2 levels following iTBS treatment
Baseline and Week 4
Change in Gene Expression Profiles
Tidsram: Baseline and Week 4
Change in gene expression levels of inflammatory and neuroprotective biomarkers measured by quantitative polymerase chain reaction (qPCR).
Baseline and Week 4

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 september 2026

Primärt slutförande (Beräknad)

1 september 2027

Avslutad studie (Beräknad)

1 september 2027

Studieregistreringsdatum

Först inskickad

23 juni 2026

Först inskickad som uppfyllde QC-kriterierna

23 juni 2026

Första postat (Faktisk)

29 juni 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

14 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

11 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

De-identified individual participant data (IPD) underlying the published results will be made available to qualified researchers upon reasonable request after publication of the primary study results. Data sharing will be subject to institutional approval and applicable ethical and legal regulations to protect participant confidentiality.

Tidsram för IPD-delning

Beginning upon publication of the primary study results and ending 5 years after publication.

Kriterier för IPD Sharing Access

De-identified individual participant data and selected supporting documents will be available to qualified researchers upon reasonable request. Access will be granted after review and approval by the principal investigator and the sponsoring institution. Data will be shared for scientific research purposes only and will require compliance with applicable ethical, legal, and institutional regulations to protect participant confidentiality.

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • ICF
  • ANALYTIC_CODE

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera